Safety update regarding intranasal corticosteroids for the treatment of allergic rhinitis

被引:46
|
作者
Blaiss, Michael S. [1 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Dept Pediat & Med, Memphis, TN USA
关键词
FUROATE NASAL SPRAY; LONG-TERM SAFETY; BECLOMETHASONE DIPROPIONATE; CICLESONIDE; CHILDREN; EFFICACY; GROWTH; MANAGEMENT; EPISTAXIS; CORTISOL;
D O I
10.2500/aap.2011.32.3473
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Initranasal corticosteroids (INSs) are the most efficacious medication for the treatment of allergic rhinitis. In 2006, the Joint Task Force of the American College of Allergy, Asthma, and immunology, and the American Academy of Allergy, Asthma, and Immunology, published a white paper on the potential over-the-counter switch of INS (Bielory L, Blaiss M, Fineman SM, et al. Concerns about intranasal corticosteroids for over-the-counter use: Position statement of the Joint Task Force for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Ann Allergy Asthma immunol 96:514-525, 2006). The concern of the paper was the safety of the use of these agents without oversight by a health care professional. The objective of this paper was to review published literature on the safety of INS since the publication of the task force white paper. Recent studies, which evaluated topical and systemic adverse events associated with ciclesonide (CIC), fluticasone furoate (FF), mometasone furoate (MF), triamcinolone acetonide, fluticasone propionate, budesonide, and beclomethasone dipropionate were summarized. In general, no significant topical or systemic complications were observed in these studies, although none were >1 year in duration. The newer formulations of topical corticosteroids for allergic rhinitis, such as CIC, FF, and MF, which have less systemic bioavailability, may be safer for long-term use. New studies continue to add to the reassurance of the safety of INSs in the treatment of allergic rhinitis but still do not answer the question if these agents are appropriate for long-term use without oversight by a health care professional. (Allergy Asthma Proc 32:413-418, 2011; doi: 10.2500/aap.2011.32.3473)
引用
收藏
页码:413 / 418
页数:6
相关论文
共 50 条
  • [1] Safety considerations of intranasal corticosteroids for the treatment of allergic rhinitis
    Blaiss, Michael S.
    ALLERGY AND ASTHMA PROCEEDINGS, 2007, 28 (02) : 145 - 152
  • [2] Intranasal corticosteroids in the treatment of allergic rhinitis
    Ratner, Paul H.
    Stoloff, Stuart
    Meltzer, Eli O.
    Hadley, James A.
    ALLERGY AND ASTHMA PROCEEDINGS, 2007, 28 (03) : S25 - S32
  • [3] Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis
    Salib, RJ
    Howarth, PH
    DRUG SAFETY, 2003, 26 (12) : 863 - 893
  • [4] Safety and Tolerability Profiles of Intranasal Antihistamines and Intranasal Corticosteroids in the Treatment of Allergic Rhinitis
    Rami Jean Salib
    Peter Hugo Howarth
    Drug Safety, 2003, 26 : 863 - 893
  • [5] Safety of intranasal corticosteroids for allergic rhinitis in children
    Zhang, Min
    Ni, Jing-Zi
    Cheng, Lei
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (07) : 931 - 938
  • [6] Intranasal corticosteroids for the treatment of perennial allergic rhinitis
    Stokes, Jeff
    SOUTHERN MEDICAL JOURNAL, 2007, 100 (07) : 667 - 668
  • [7] Intranasal corticosteroids for allergic rhinitis
    Trangsrud, AJ
    Whitaker, AL
    Small, RE
    PHARMACOTHERAPY, 2002, 22 (11): : 1458 - 1467
  • [8] Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis
    Meltzer, Eli O.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2007, 98 (01) : 12 - 21
  • [9] Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis
    Schaefer, T.
    Schnoor, M.
    Wagenmann, M.
    Klimek, L.
    Bachert, C.
    RHINOLOGY, 2011, 49 (03) : 272 - 280
  • [10] Preferences of intranasal corticosteroids in children with allergic rhinitis
    Emeryk, A.
    Markut-Miota, E.
    Kowalska, M.
    Nowosad, A.
    Bartkowiak-Emeryk, M.
    Donka, K.
    ALLERGY, 2011, 66 : 192 - 192